Fund Advisors of America Inc FL Invests $897,000 in AbbVie Inc. $ABBV

Fund Advisors of America Inc FL bought a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 3,925 shares of the company’s stock, valued at approximately $897,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Chelsea Counsel Co. bought a new position in AbbVie during the third quarter worth about $26,000. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie in the 4th quarter valued at approximately $28,000. Imprint Wealth LLC grew its stake in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the period. Westend Capital Management LLC acquired a new position in shares of AbbVie in the 4th quarter worth approximately $29,000. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of AbbVie in the 4th quarter worth approximately $31,000. Institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. William Blair reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Thursday, April 30th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $240.00 target price on shares of AbbVie in a report on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $253.43.

AbbVie Price Performance

Shares of ABBV opened at $216.63 on Friday. The company has a market capitalization of $382.74 billion, a P/E ratio of 106.71, a PEG ratio of 0.66 and a beta of 0.32. AbbVie Inc. has a one year low of $181.73 and a one year high of $244.81. The business’s 50 day simple moving average is $212.18 and its 200-day simple moving average is $218.76.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period last year, the firm posted $2.46 EPS. The business’s revenue was up 12.4% on a year-over-year basis. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is 340.89%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.